SecBot SecBot
COURT-RULING ·Filed May 28, 2026

ABT

ABBOTT LABORATORIES
NEUTRAL
Impact 1/10
Horizonimmediate Processed5mo ago CourtCourt Ruling · courtlistener.com
Court ruling (appellate)
Actionable Insight • Neutral

This ruling has no material impact on Abbott's stock. The case was a pro se employment suit dismissed at the pleading stage, and the affirmance merely confirms that outcome. No further action or monitoring is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$86.24
T+0 close · May 28, 2026 · via day close
Latest settled
+35.24%
T+60 · $116.63
Vs SPY
+33.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 28 $86.24entry
  2. T+1 · 6mo ago −0.86%α −1.10% · $85.50
  3. T+5 · 6mo ago +0.87%α +0.92% · $86.99
  4. T+20 · 5mo ago +8.12%α +10.81% · $93.24
  5. T+60 · 3mo ago +35.24%α +33.77% · $116.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The Ninth Circuit affirmed the district court's dismissal of a pro se plaintiff's employment claims against Abbott Laboratories for failure to state a claim. The ruling is a complete win for Abbott, removing a trivial litigation risk with no financial exposure.

Court Ruling Details

Ruling Date
May 28, 2026
Court
United States Court of Appeals for the Ninth Circuit
Court Level
Appellate
Judge
S.R. Thomas, Miller, H.A. Thomas
Case Type
employment
Ruling Type
final judgment
Outcome
WIN: ruling favors this company
Precedent Risk
LOW

Key Facts

  • Ninth Circuit affirmed dismissal of employment claims against Abbott Laboratories
  • Plaintiff Mazen Arakji failed to allege facts sufficient to state a plausible claim
  • Ruling is a final judgment in Abbott's favor with no damages awarded or sought
  • Case involved routine employment claims with no material financial exposure

Financial Impact

No damages awarded or pleaded; case dismissed with no financial impact on Abbott

Market Snapshot

Price
$85.82
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-1w7g8o9x-ABT

Track record

38 reports on ABT

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +17.16% at T+20 after the Jul 1, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 5, 202611d ago 144 Neutral 2/10 Entry $109.93 Now $107.45 −2.26% settles Dec 7
  2. Oct 27, 202620d ago ANALYST-DOWNGRADE Neutral 2/10 Entry $103.10 Now $107.45 +4.22% settles Nov 24
  3. Oct 27, 202621d ago Court Ruling Neutral 1/10 Entry $102.64 Now $107.45 +4.69% settles Nov 25
  4. Oct 21, 202626d ago Institutional Cluster Mixed 4/10 Entry $102.51 Now $107.45 +4.82% settles Nov 19
  5. Oct 21, 202626d ago 8-K Bullish 6/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
  6. Oct 21, 202626d ago 8-K Bearish 6/10 No price data
  7. Oct 21, 202626d ago Press Release Neutral 4/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
  8. Oct 20, 202628d ago Court Ruling Neutral 1/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
  9. Oct 16, 20264w ago Court Ruling Neutral 2/10 Entry $104.06 to $107.45 Now $107.45 +3.26% ▲ +3.26% +6.72% vs SPY
  10. Oct 15, 20264w ago Court Ruling Bullish 5/10 Entry $104.89 to $108.52 Now $107.45 +2.44% ▲ +3.46% +4.62% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (11h 22m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published May 28, 2026